MMP9 and Hepatic fibrosis: To validate this hypothesis, we developed an immunological assay detecting a neo-epitope of biglycan generated by MMP-9 and MMP-12 cleavage (BGM) in serum, and measured the levels of this marker in one rat model of RA and in two rat models of liver fibrosis, chosen as model pathologies involving disrupted ECM turnover.